NOVARTIS AG-SPONSORED ADR (NVS) Top Institutional Shareholders
NOVARTIS AG-SPONSORED ADR (NVS) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended March 31, 2026. The institutional investors covered on this page collectively reported approximately $1.26B in NVS holdings during the latest filing period.
Dodge & Cox Stock Fund is currently the largest disclosed institutional shareholder of NVS tracked by InsiderSet, reporting ownership valued at approximately $1.06B in its March 31, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $1.07B, representing an estimated gain of +0.41% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed NVS value among the investors covered in this analysis. Major shareholders include Dodge & Cox Stock Fund, Renaissance Technologies LLC, Tweedy, Browne Co All Funds (US), and several other long-term asset managers with concentrated positions in NOVARTIS AG-SPONSORED ADR (NVS).
This page ranks the largest institutional NVS shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | V. D. Dodge, E. M. Cox | 0.58% | 6,967,383 | $1,064,267,753 | $1,068,657,205 | +$4,389,452 | +0.41% |
| Renaissance Technologies LLC | Jim Simons | 0.27% | 1,111,833 | $169,832,491 | $170,532,946 | +$700,455 | +0.41% |
| Tweedy, Browne Co All Funds (US) | B. Tweedy, Ch. Browne | 0.87% | 71,305 | $10,891,839 | $10,936,761 | +$44,922 | +0.41% |
| Cullen Value Fund | Jim Cullen | 1.01% | 50,305 | $7,682,369 | $7,715,781 | +$33,412 | +0.43% |
| Sequoia Financial Advisors | 0.04% | 42,951 | $6,560,711 | $6,587,824 | +$27,113 | +0.41% | |
| Kahn Brothers Group | Thomas Graham, Alan, Irving Kahns | 0.36% | 13,386 | $2,044,711 | $2,053,145 | +$8,434 | +0.41% |
| Parnassus Endeavor Fund | Parnassus Investments | 0.00% | 1,999 | $305,347 | $306,607 | +$1,260 | +0.41% |
| Causeway Capital Management | Sarah Ketterer | 0.00% | 1,487 | $227,167 | $228,076 | +$909 | +0.40% |
Frequently asked questions about NVS
Who owns the most NVS stock?
The largest holders of NVS are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for NOVARTIS AG-SPONSORED ADR (NVS).
Is NVS widely held by superinvestors?
Many widely followed stocks like NVS appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly NVS is represented among the institutional managers we track.
What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?
Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.